Banner Life Sciences, LLC
$92.8K 2,044 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation reported $92,749.10 across General Payments, Research, and Ownership to 45 physicians and teaching hospitals across 45 transactions.
- $92.7K Below-median payer
- All-tracks total
- 45 Below-median volume
- Transactions
- 45 Below-median reach
- Recipients
- +$5.7K
- General Payments vs PY2023
Mitsubishi Tanabe Pharma Corporation reported $92,749.10 across all CMS Open Payments tracks (General + Research + Ownership) to 45 physicians and teaching hospitals in Program Year 2024 - ranking #1203 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $92,749.10, averaging $2.1K per recipient.
Mitsubishi Tanabe Pharma Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mitsubishi-tanabe-pharma-corporation Mitsubishi Tanabe Pharma Corporation
$92.7K · #1203/1,925 · 0.0% industry · PY2024
- TOT $92.7K
- RANK #1203
- SHARE 0.0%
- TXN 45
- RCP 45
- CAT 3
- GEN $92.7K
- ΔGEN +$5.7K
- TOP1 22.4%
- PY 2024
Volume peers
Nearest volume peer: Banner Life Sciences, LLC ($92.8K)
Mitsubishi Tanabe Pharma Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Mitsubishi Tanabe Pharma Corporation's CMS-reported General Payments increased by $5.7K (+6.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TANABE PHARMA CORPORATIONPY2023: TANABE PHARMA CORPORATIONPY2024: MITSUBISHI TANABE PHARMA CORPORATION. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $87,098.21
- PY2024
- $92,749.10
What the Data Shows for Mitsubishi Tanabe Pharma Corporation
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Mitsubishi Tanabe Pharma Corporation that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Travel and Lodging" leads the 3-category general-payment breakdown below at $65.6K (70.8% of General Payments, 22 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Travel and Lodging" leads Mitsubishi Tanabe Pharma Corporation's 3-category general-payment breakdown at $65.6K, 70.8% of the reported total.
How Mitsubishi Tanabe Pharma Corporation divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $65.6K | 22 | 70.8% |
| Compensation for Services Other Than Consulting | $26.4K | 15 | 28.4% |
| Food and Beverage | $739.71 | 8 | 0.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $82,239.25 (88.7%) of $92,749.10 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mitsubishi Tanabe Pharma Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Jeffrey Bennett
$20,751.83 across 6 reported transactions
- 2
Maria Delas Mercedes Perez Rodriguez
$17,856.79 across 7 reported transactions
- 3
Daniel Podolsky
$17,462.90 across 4 reported transactions
- 4
Bruce Sands
$15,657.49 across 8 reported transactions
- 5
Nilay S Sethi
$10,510.24 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mitsubishi Tanabe Pharma Corporation ranks #1203 of 1,925 by total payments (bottom 38% by spend) but is notably more concentrated than that alone would suggest -- #813 of 1,838 by HHI (top 44% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Albireo Pharma, Inc. : $317.2K total payments, HHI 1739
- Puma Biotechnology, Inc. : $396.8K total payments, HHI 1733
- Pulse Biosciences, Inc. : $534.8K total payments, HHI 1730
- SS White Burs, Inc. : $65.6K total payments, HHI 1718
- Maquet Cardiovascular L.L.C. : $188.3K total payments, HHI 1714
- GS Solutions, Inc. : $38.7K total payments, HHI 1706
- Mitsubishi Tanabe Pharma Corporation (this company) : $92.7K total payments, HHI 1705
- TerSera Therapeutics LLC : $602.9K total payments, HHI 1704
- Agilent Technologies, Inc. : $1.2M total payments, HHI 1698
- Bolder Surgical, LLC : $49.7K total payments, HHI 1698
- Dompe Farmaceutici S.p.A. : $11.8K total payments, HHI 1694
- Amicus Therapeutics, Inc. : $684.6K total payments, HHI 1692
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mitsubishi Tanabe Pharma Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mitsubishi Tanabe Pharma Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mitsubishi Tanabe Pharma Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Mid-Atlantic Surgical Systems, LLC
$92.4K 919 recipients
Compare payment profiles
Cardinal Health 110 LLC
$92.3K 166 recipients
Compare payment profiles
Okami Medical, Inc.
$92.0K 263 recipients
Compare payment profiles
OnMark, Inc.
$93.7K 63 recipients
Compare payment profiles
AGEPHA Pharma FZ LLC
$93.7K 510 recipients
Compare payment profiles
Put this to use
Mitsubishi Tanabe Pharma Corporation ranks #1203 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Mitsubishi Tanabe Pharma Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.